Long-term treatment with odanacatib maintains normal trabecular biomechanical properties in ovariectomized adult monkeys as demonstrated by micro-CT-based finite element analysis

Autor: Antonio Cabal, Donald S. Williams, Richa Y. Jayakar, Jingru Zhang, Swanand Sardesai, Le T. Duong

Publikováno v: Bone Reports, Vol 6, Iss C, Pp 26-33 (2017)

The cathepsin K inhibitor odanacatib (ODN) is a potent and reversible inhibitor of osteoclastic resorption activity. This drug is currently under development for the treatment of postmenopausal osteoporosis. Previously, we described data on the treat

Externí odkaz: https://doaj.org/article/f928a5ab9cbe4d71bb8d918e6d7b3bf4

Effects of odanacatib on bone matrix mineralization in rhesus monkeys are similar to those of alendronate

Autor: Barbara M. Misof, Paul Roschger, Charles Chen, Maureen Pickarski, Phaedra Messmer, Klaus Klaushofer, Le T. Duong

Publikováno v: Bone Reports, Vol 5, Iss , Pp 62-69 (2016)

Odanacatib (ODN) is a selective and reversible inhibitor of cathepsin K which is an important enzyme for the degradation of collagen I. Aim of the present work was the head-to-head comparison between the effects of ODN and alendronate (ALN) on bone m

Externí odkaz: https://doaj.org/article/00b5e204419c42a4b586d6915559e1d2

Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5‐Year Data From the Phase 3 Long‐Term Odanacatib Fracture Trial (LOFT) and its Extension

Autor: Robert R. Recker, Le T. Duong, Tobias J. de Villiers, Arthur C. Santora, Seth Clark, David W. Dempster, Hilde Giezek, Bente L. Langdahl, Ivo Valter, Cristiano A. F. Zerbini, D Cohn, Graham Ellis

Publikováno v: Recker, R, Dempster, D, Langdahl, B, Giezek, H, Clark, S, Ellis, G, de Villiers, T, Valter, I, Zerbini, C A F, Cohn, D, Santora, A & Duong, L T 2020, ' Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women with Osteoporosis : 5-year Data from the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension ', Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, vol. 35, no. 7, pp. 1289-1299 . https://doi.org/10.1002/jbmr.3994

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, was an investigational agent previously in development for the treatment of osteoporosis. In this analysis, the effects of ODN on bone remodeling/modeling and structure were examined in the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c1d206b61cde3dd1f3a0db7ee0dc508
https://doi.org/10.1002/jbmr.3994

Author response for 'Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women with Osteoporosis: 5‐year Data from the Phase 3 Long‐Term Odanacatib Fracture Trial (LOFT) and its Extension'

Autor: null Robert Recker, null David Dempster, null Bente Langdahl, null Hilde Giezek, null Seth Clark, null Graham Ellis, null Tobias Villiers, null Ivo Valter, null Cristiano A.F. Zerbini, null Dosinda Cohn, null Arthur Santora, null Le T. Duong

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::040550212e92938c1d89b8005b96f4d6
https://doi.org/10.1002/jbmr.3994/v2/response1

Articular cartilage protection in Ctsk ‐/‐ mice is associated with cellular and molecular changes in subchondral bone and cartilage matrix

Autor: Fabiana N. Soki, Marc F. Hansen, David N. Paglia, Ryu Yoshida, Hicham Drissi, Le T. Duong

Publikováno v: Journal of Cellular Physiology. 233:8666-8676

Osteoarthritis (OA) is a degenerative disease and a major cause of chronic disability in aging individuals. Cathepsin K (CatK), encoded by the Ctsk gene, has been implicated in the pathogenesis of pycnodysostosis and osteoporosis. The use of a select

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de38a99938f524728c6fb36cfed6feb7
https://doi.org/10.1002/jcp.26745